Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence
- 14 July 2009
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 25 (9), 2159-2165
- https://doi.org/10.1185/03007990903103279
Abstract
Objective: To assess the effects of tolterodine extended release (ER) on patient-reported outcomes (PROs) in sexually active women with overactive bladder (OAB) and urgency urinary incontinence (UUI). Research design and methods: This multicenter, double-blind, placebo controlled trial included 411 women aged ≥18 years reporting OAB symptoms for ≥3 months; ≥8 micturitions per 24 hours (including ≥0.6 UUI episodes and ≥3 OAB micturitions) in 5-day bladder diaries at baseline, and being in a sexually active relationship for ≥6 months. Subjects randomized to placebo or tolterodine ER completed validated OAB- or incontinence-specific questionnaires, including the Patient Perception of Bladder Condition (PPBC), Overactive Bladder Questionnaire (OAB-q), Urgency Perception Scale (UPS), and the Incontinence Impact Questionnaire (IIQ) at baseline and week 12, as well as the Perception of Treatment Benefit and Treatment Satisfaction questions at week 12. This study is registered with ClinicalTrials.gov (identifier: NCT00143481) Results: The mean age of enrolled women was approximately 48 years. Compared with placebo, the tolterodine ER group reported significant baseline to week 12 improvements in PPBC responses (p = 0.0048); OAB-q Symptom Bother, total Health-Related Quality of Life (HRQL), and HRQL domain scores (all p < 0.05); IIQ Emotional Health domain scores (p < 0.05); proportions of subjects reporting treatment benefit (79 vs. 54%; p < 0.0001) and satisfaction (78 vs. 59%; p < 0.0001). Improvements on the UPS were not significantly different. Conclusions: Tolterodine ER treatment was associated with improvements in multiple OAB- and incontinence-specific PROs in a sexually active, relatively young, and racially diverse population of women. The findings provide clinicians with new insights into the impact of OAB and its treatment on HRQL in this population, which has been underrepresented in previous OAB studies. Study limitations include a potential underestimation of the impact of OAB symptoms resulting from the exclusion of women who may not be sexually active because of their urinary symptoms.Keywords
This publication has 24 references indexed in Scilit:
- Premenopausal Women with Sexual Dysfunction: The Need for a Bladder Function HistoryThe Journal of Sexual Medicine, 2008
- Overactive Bladder and Women's Sexual Health: What is the Impact?The Journal of Sexual Medicine, 2007
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Reviewing the ICS 2002 terminology report: The ongoing debateNeurourology and Urodynamics, 2006
- Impact of overactive bladder symptoms on employment, social interactions and emotional well‐being in six European countriesBJU International, 2005
- Overactive bladder in women: symptom impact and treatment expectationsCurrent Medical Research and Opinion, 2005
- The Impact of Urinary Urgency and Frequency on Health-Related Quality of Life in Overactive Bladder: Results from a National Community SurveyValue in Health, 2004
- Severe depression determines quality of life in urinary incontinent womenNeurourology and Urodynamics, 2003
- The effect of urinary incontinence and overactive bladder symptoms on quality of life in young womenBJU International, 2002
- How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence studyBJU International, 2001